Although common among lung cancer patients of Asian descent (10), sensitizing EGFR mutations are relatively uncommon in North American and European NSCLC populations with a prevalence of ~15% in patients with advanced non-squamous histology (11). The gene discussed is EGFR; the disease is lung carcinoma.